

TARGETED GENETICS CORP /WA/  
Form 8-K  
July 17, 2003

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) July 15, 2003**

---

**Targeted Genetics Corporation**

(Exact name of registrant as specified in charter)

<b>Washington</b> (State or other	<b>0-23930</b> (Commission	<b>91-1549568</b> (IRS Employer
<b>jurisdiction of incorporation)</b>	<b>File Number)</b>	<b>Identification No.)</b>
<b>1100 Olive Way, Suite 100, Seattle, Washington</b> (Address of principal executive offices)		<b>98101</b> (Zip Code)

**(206) 623-7612**

**Registrant's telephone number, including area code**

**Not Applicable**

**(Former name or former address, if changed since last report)**

---

**Item 5. Other Events.**

On July 15, 2003, Targeted Genetics Corporation announced the initiation of a Phase IIb clinical trial of tgAAVCF in patients with cystic fibrosis. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference.

**Item 7. Exhibits.**

- (a) Financial statements of business acquired.

Not applicable.

- (b) Pro forma financial information.

Not applicable.

- (c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated July 15, 2003

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

Date: July 16, 2003

By:

/s/ TODD E. SIMPSON

---

Todd E. Simpson

Vice President, Finance and Administration and

Chief Financial Officer, Secretary and Treasurer

(Principal Financial and Accounting Officer)

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated July 15, 2003